by Admin | Mar 14, 2026 | Inspections & Compliance
MHRA has reviewed how risk information is communicated for gabapentinoids, benzodiazepines, and z-drugs and concluded that warnings on these medicines need to be strengthened. The agency said it was necessary to improve the warnings regarding addiction, dependence,...
by Admin | Mar 13, 2026 | Inspections & Compliance
On 5 March 2026, the FDA issued a warning letter to Novo Nordisk Inc. describing objectionable conditions observed during an inspection that reviewed the company’s compliance with postmarketing adverse drug experience (PADE) regulations. According to the letter, the...